GSA Capital Partners’s Acrivon Therapeutics ACRV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$429K Buy
209,355
+8,940
+4% +$17K 0.03% 1164
2026
Q2
$357K Buy
200,415
+13,699
+7% +$23.3K 0.02% 1210
2026
Q1
$260K Buy
+186,716
New +$326K 0.02% 1327

Other funds holding ACRV

GSA Capital Partners's ACRV Position: Q3 2026 in Review

GSA Capital Partners increased its Acrivon Therapeutics (ACRV) stake by 4.5% in Q3 2026, buying an estimated $17K and bringing the position to 209,355 shares worth $429K. The position accounts for 0.03% of the portfolio, ranked #1164.

GSA Capital Partners first reported a position in ACRV in Q1 2026 and has held it in 3 quarters since. 46 funds tracked by Wall St. Rank hold ACRV as of Q3 2026.

  • GSA Capital Partners held 209,355 shares of Acrivon Therapeutics worth $429K as of Q3 2026.
  • GSA Capital Partners bought 8,940 Acrivon Therapeutics shares in Q3 2026, an estimated $17K.
  • Acrivon Therapeutics made up 0.03% of GSA Capital Partners's portfolio in Q3 2026, its #1164 holding.
  • GSA Capital Partners first reported a position in Acrivon Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 46 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q3 2026.

Based on GSA Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.